The number of US adults living with heart failure has more than doubled over the past three decades, mostly due to the rising ...

The NY Center for the Prevention of Heart Disease announces expanded services for heart failure patients in Midtown Manhattan ...

Achieving equitable access to anti-fibrotic drugs requires multi-stakeholder collaboration, while the most critical unmet ...

MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCMFDA Approval Based on ...

ST. MARYS — Grand Lake Health System earned a certificate from a nationally recognized health care accreditation firm for excellence in diagnosis, treatment and management of heart failure patients.

The US Food and Drug Administration has approved aficamten (Myqorzo), an allosteric cardiac myosin inhibitor, for adults with ...

PRNewswire/ -- The December issue of the Journal of Cardiac Failure (JCF), now available, offers a robust lineup of original research, expert consensus, and clinical insights that explore heart ...

Stacy Sharpe is the Lead Nurse Navigator at the Office of Community Health and Chattanooga’s sharpest defense against the gap ...

For patients with diabetes, the days after hospital discharge can be as risky as the days leading up to admission. Clinicians say the transition from inpatient to outpatient care remains one of the ...

Cytokinetics announced FDA approval of MYQORZO™ (aficamten) to treat adults with symptomatic obstructive hypertrophic ...

Here are the top IVBM articles from 2025 capturing how value-based strategies are translating into real-world impact. Click ...

Recognized with awards such as a Stevie Healthcare Technology Company of the Year, 2024 Digital Health Award, and Merit Award for Connected Digital Health, Brook.ai is combining technology and human ...